ScreenerHero

ARQTArcutis Biotherapeutics, Inc.

NAS · US · Healthcare · Biotechnology · arcutis.com
25.08USD-5.22%Mkt Cap: 3.15B $P/E: 114.00

Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. The company's lead product is ZORYVE, a topical roflumilast cream for the trea…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$138.82BUSDP/E 31.9
REGN
Regeneron Pharmaceuticals, Inc.
$85.87BUSDP/E 20.5
ARGX
ARGENX SE
$61.34BUSDP/E 39.8
ARGX
argenx SE
$65.05BUSDP/E 39.6
MRNA
Moderna, Inc.
$57.94BUSD
UCB
UCB SA
$45.95BUSDP/E 19.6
RVMD
Revolution Medicines, Inc.
$44.89BUSD
ONC
BeOne Medicines AG
$42.36BUSDP/E 67.2
RPRX
Royalty Pharma Plc Class A
$35.43BUSDP/E 32.6
ALNY
Alnylam Pharmaceuticals, Inc.
$31.61BUSDP/E 41.2
BNTX
BioNTech SE
$29.28BUSD
INSM
Insmed Incorporated
$27.47BUSD
ROIV
Roivant Sciences Ltd. Common Shares
$26.22BUSD
INCY
Incyte Corporation
$25.91BUSDP/E 16.2
GMAB
Genmab A/S
$20.86BUSDP/E 26.3
GMAB
Genmab A/S
$19.26BUSDP/E 26.6
ASND
Ascendis Pharma A/S
$16.61BUSDP/E 19.6
JAZZ
Jazz Pharmaceuticals plc
$16.51BUSDP/E 17.4
BBIO
BridgeBio Pharma, Inc.
$15.93BUSD
EXEL
Exelixis, Inc.
$13.40BUSDP/E 17.0

Key Statistics

Company
Market Cap3.15B $
Enterprise Value3.06B $
Revenue (TTM)463.98M $
Gross Profit339.38M $
Net Income (TTM)-16.14M $
Revenue/Share3.598 USD
Last Price25.08 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees354
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)114.00
P/E (Forward)19.45
PEG—
EV/EBITDA83.88
EV/Revenue6.60
P/S6.87
P/B14.44
EPS (TTM)0.21
EPS (Forward)1.30
52W Range
15.1060% of range31.77
52W High31.77 USD
52W Low15.10 USD
Profitability
Gross Margin90.24%
Oper. Margin12.65%
EBITDA Margin7.87%
Profit Margin-4.29%
ROE-8.52%
ROA-3.73%
Growth
Revenue Growth59.30%
Earnings Growth—
Cash Flow & Leverage
Operating CF-5.63M $
CapEx (TTM)10.69M $
FCF Margin4.67%
FCF Yield0.69%
Net Debt-124.42M $
Net Debt/EBITDA-3.41
Balance Sheet
Debt/Equity0.60
Current Ratio2.92
Quick Ratio2.46
Book Value/Sh1.756 USD
Cash/Share1.898 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating1.5 (Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)36.88 USD
Upside (mean)+47.0%
Target Range34.00 USD – 40.00 USD
$34.00+47.0% to mean$40.00
# Analysts8
Ownership
Shares Out.125.69M
Float92.87M
Insiders1.78%
Institutions108.80%
Short Interest
Short Ratio9.6d
Short % Float10.76%
Short % Out.10.09%
Shares Short12.69M
Short (prev mo.)14.02M
Technical
SMA 5026.67 (-6.0%)
SMA 20025.61 (-2.1%)
Beta1.53
S&P 52W Chg18.16%
Avg Vol (30d)1.37M
Avg Vol (10d)1.75M
Technical Indicators
RSI (14)42.2
MACD-0.2555
MACD Signal-0.0797
MACD Hist.-0.1758
BB Upper28.50 USD
BB Middle26.60 USD
BB Lower24.71 USD
BB Width14.25%
ATR (14)1.197 USD
Vol Ratio (20d)1.59x